Mcgowan, I and Cranston, RD and Duffill, K and Siegel, A and Engstrom, JC and Nikiforov, A and Jacobson, C and Rehman, KK and Elliott, J and Khanukhova, E and Abebe, K and Mauck, C and Spiegel, HML and Dezzutti, CS and Rohan, LC and Marzinke, MA and Hiruy, H and Hendrix, CW and Richardson-Harman, N and Anton, PA
(2015)
A phase 1 randomized, open label, rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of three formulations of tenofovir 1% Gel (the CHARM-01 study).
PLoS ONE, 10 (5).
Abstract
Objectives: The CHARM-01 study characterized the safety, acceptability, pharmacokinetics (PK), and pharmacodynamics (PD) of three tenofovir (TFV) gels for rectal application. The vaginal formulation (VF) gel was previously used in the CAPRISA 004 and VOICE vaginal microbicide Phase 2B trials and the RMP-02/MTN-006 Phase 1 rectal safety study. The reduced glycerin VF (RGVF) gel was used in the MTN-007 Phase 1 rectal microbicide trial and is currently being evaluated in the MTN-017 Phase 2 rectal microbicide trial. A third rectal specific formulation (RF) gel was also evaluated in the CHARM-01 study. Methods: Participants received 4 mL of the three TFV gels in a blinded, crossover design: seven daily doses of RGVF, seven daily doses of RF, and six daily doses of placebo followed by one dose of VF, in a randomized sequence. Safety, acceptability, compartmental PK, and explant PD were monitored throughout the trial. Results: All three gels were found to be safe and acceptable. RF and RGVF PK were not significantly different. Median mucosal mononuclear cell (MMC) TFV-DP trended toward higher values for RF compared to RGVF (1136 and 320 fmol/10<sup>6</sup> cells respectively). Use of each gel in vivo was associated with significant inhibition of ex vivo colorectal tissue HIV infection. There was also a significant negative correlation between the tissue levels of TFV, tissue TFV-DP, MMC TFV-DP, rectal fluid TFV, and explant HIV-1 infection. Conclusions: All three formulations were found to be safe and acceptable. However, the safety profile of the VF gel was only based on exposure to one dose whereas participants received seven doses of the RGVF and RF gels. There was a trend towards higher tissue MMC levels of TFV-DP associated with use of the RF gel. Use of all gels was associated with significant inhibition of ex vivo tissue HIV infection. Trial Registration: ClinicalTrials.gov NCT01575405.
Share
Citation/Export: |
|
Social Networking: |
|
Details
Item Type: |
Article
|
Status: |
Published |
Creators/Authors: |
Creators | Email | Pitt Username | ORCID ![](/images/orcid_id_24x24.png) |
---|
Mcgowan, I | imcgowan@pitt.edu | IMCGOWAN | | Cranston, RD | rdc27@pitt.edu | RDC27 | | Duffill, K | | | | Siegel, A | | | | Engstrom, JC | | | | Nikiforov, A | | | | Jacobson, C | | | | Rehman, KK | | | | Elliott, J | | | | Khanukhova, E | | | | Abebe, K | kza3@pitt.edu | KZA3 | | Mauck, C | | | | Spiegel, HML | | | | Dezzutti, CS | csd13@pitt.edu | CSD13 | | Rohan, LC | | | | Marzinke, MA | | | | Hiruy, H | | | | Hendrix, CW | | | | Richardson-Harman, N | | | | Anton, PA | | | |
|
Contributors: |
Contribution | Contributors Name | Email | Pitt Username | ORCID ![](/images/orcid_id_24x24.png) |
---|
Editor | Lama, Javier R | UNSPECIFIED | UNSPECIFIED | UNSPECIFIED |
|
Centers: |
Other Centers, Institutes, Offices, or Units > Magee-Women's Research Institute |
Date: |
5 May 2015 |
Date Type: |
Publication |
Access Restriction: |
No restriction; Release the ETD for access worldwide immediately. |
Journal or Publication Title: |
PLoS ONE |
Volume: |
10 |
Number: |
5 |
DOI or Unique Handle: |
10.1371/journal.pone.0125363 |
Institution: |
University of Pittsburgh |
Refereed: |
Yes |
Date Deposited: |
23 Aug 2016 14:05 |
Last Modified: |
30 Mar 2021 13:56 |
URI: |
http://d-scholarship.pitt.edu/id/eprint/28481 |
Metrics
Monthly Views for the past 3 years
Plum Analytics
Altmetric.com
Actions (login required)
![View Item View Item](/style/images/action_view.png) |
View Item |